share_log

Jefferies Maintains Buy on Replimune Group, Raises Price Target to $19

Benzinga ·  Dec 4 02:53  · Ratings

Jefferies analyst Roger Song maintains Replimune Group (NASDAQ:REPL) with a Buy and raises the price target from $16 to $19.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment